skip to Main Content

Gemcitabine Combined with the Monoclonal Antibody Nimotuzumab is an Active First-Line Regimen in KRAS Wildtype Patients with Locally Advanced or Metastatic Pancreatic Cancer: a Multicenter, Randomized Phase IIb Study

Newsfeed image, light gray text on dark gray background
This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-EGFR monoclonal antibody, compared to gem plus placebo as first-line therapy in patients with advanced pancreatic cancer.

Read more . . .

Back To Top